Immtech International has announced that all 30 patients participating in the concluded Phase IIb extended dose regimen arm of its clinical trial of DB289 for treating African sleeping sickness cleared the parasite that causes African sleeping sickness within the treatment period, with no significant adverse results reported.
This arm of the open label trial used DB289 as treatment twice per day (100 mg each dose) for ten days. The medical investigators will continue to monitor the patients for re-occurrence of the disease at 3, 6, and 12 months. The study was conducted at two sites in the Democratic Republic of the Congo-Maluku (located near the capital Kinshasa) and Vanga (centrally located in the country).
T. Stephen Thompson, President and CEO of Immtech, said, "We are pleased with the preliminary results of this study, which will be incorporated in the upcoming randomized open label Phase III pivotal study to be conducted at multiple sites in Angola and the Democratic Republic of Congo."
Immtech International, Inc. is a pharmaceutical company advancing the development of treatments for fungal infections, malaria, tuberculosis, cancer, diabetes, Pneumocystis carinii pneumonia ("PCP") and tropical diseases, including African sleeping sickness (trypanosomiasis) and leishmaniasis.